D4S:FRA
Daiichi Sankyo Co Ltd
€ १४.४५
arrow_upward
+२.४८%(+०.३५) 1D
मे २२, २२:००:०० GMT+२ · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for D4S...
Open
€ १४.१५
High
€ १४.४५
Low
€ १४.१५
Mkt. cap
३१.७३ अरब
Avg. vol.
२०७.००
Volume
४००.००
52-wk high
€ २३.९१
52-wk low
€ १३.५७
No. of employees
२० हजार
News stories
From sources across the web
London South East
·
१ दिन पहिले
AstraZeneca and Daiichi cancer drugs clear regulatory hurdles
Investing.com Canada
·
१ दिन पहिले
Enhertu receives EU approval recommendation for HER2+ solid tumors By Investing.com
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees१९.८ हजार
Founded२००५ सेप्टेम्बर २८
HeadquartersChuo City, टोक्यो, जापान
Sector-
Websitedaiichisankyo.co.jp
AI content may include mistakes. Learn more